Delving into the epigenetics of CAR T cell therapy
Chimeric antigen receptor T cells (CAR Ts) are a new approach for boosting a patient’s immune system to fight cancer. CAR Ts are patient cells engineered to detect specific antigens on cancer cells and destroy them. The scope of the EU-funded EPI-CART project is to increase our understanding of CAR Ts from an epigenetic perspective, something that hasn’t been investigated before. Researchers will undertake epigenetic and transcriptomic profiling of these cells after transplantation. Linking this information with immune regulation will uncover epigenetic drivers of CAR T cell response and help optimise this immunotherapy for solid tumours.
Fields of science
Call for proposal
See other projects for this call